In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Lykkesfeldt, Anne E ^a   Henriksen, Katrine L ^a   Rasmussen, Birgitte B ^b   Sasano, Hironobu ^c   Evans, Dean B ^d   Møller, Susanne ^e   Ejlertsen, Bent ^e   Mouridsen, Henning T ^e  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT RESPONSE; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA IN SITU; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NITRILES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TRIAZOLES;

EID: 67650021089     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-185     Document Type: Article

References (58)

1. Bonneterre J Buzdar A Nabholtz JM Robertson JF Thurlimann B von EM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 2001, 92:2247-2258. 11745278 10.1002/ 1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
2. Mouridsen H Gershanovich M Sun Y Perez-Carrion R Boni C Monnier A et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 2001, 19:2596-2606. 11352951
3. Mouridsen H Gershanovich M Sun Y Perez-Carrion R Boni C Monnier A et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 2003, 21:2101-2109. 10.1200/JCO.2003.04.194 12775735
4. Nabholtz JM Buzdar A Pollak M Harwin W Burton G Mangalik A et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 2000, 18:3758-3767. 11078488
5. Paridaens RJ Dirix LY Beex LV Nooij M Cameron DA Cufer T et al. Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 2008, 26:4883-4890. 10.1200/ JCO.2007.14.4659 18794551
6. Wardley A The need for advanced breast cancer treatment guidelines: results of an internet-based survey Breast 2008, 17:275-281. 10.1016/ j.breast.2007.10.014 18065223
7. Jensen EV Estrogen receptors in hormone-dependent breast cancers Cancer Res 1975, 35:3362-3364. 172222
8. Early Breast Cancer Trialists'Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0 15894097
9. Bardou VJ Arpino G Elledge RM Osborne CK Clark GM Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 2003, 21:1973-1979. 10.1200/JCO.2003.09.099 12743151
10. Osborne CK Yochmowitz MG Knight WA III McGuire WL The value of estrogen and progesterone receptors in the treatment of breast cancer Cancer 1980, 46:2884-2888. 10.1002/1097-0142(19801215)46:12+ <2884::AID-CNCR2820461429>3.0.CO;2-U 7448733
11. Viale G Regan MM Maiorano E Mastropasqua MG Dell'Orto P Rasmussen BB et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 2007, 25:3846-3852. 10.1200/ JCO.2007.11.9453 17679725
12. Elledge RM Green S Pugh R Allred DC Clark GM Hill J et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study Int J Cancer 2000, 89:111-117. 10754487 10.1002/ (SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
13. Geisler J Haynes B Anker G Dowsett M Lonning PE Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 2002, 20:751-757. 10.1200/JCO.20.3.751 11821457
14. Geisler J Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators J Steroid Biochem Mol Biol 2003, 86:245-253. 10.1016/S0960-0760(03)00364-9 14623518
15. Geisler J Lonning PE Aromatase inhibition: Translation into a successful therapeutic approach Clin Cancer Res 2005, 11:2809-2821. 10.1158/ 1078-0432.CCR-04-2187 15837728
16. Reed MJ Owen AM Lai LC Coldham NG Ghilchik MW Shaikh NA et al. In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione Int J Cancer 1989, 44:233-237. 10.1002/ijc.2910440208 2759729
17. de Jong PC van d V Nortier HW Maitimu-Smeele I Donker TH Thijssen JH et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole Cancer Res 1997, 57:2109-2111. 9187104
18. Geisler J Berntsen H Lonning PE A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue J Steroid Biochem Mol Biol 2000, 72:259-264. 10.1016/S0960-0760(00)00036-4 10822015
19. Geisler J Detre S Berntsen H Ottestad L Lindtjorn B Dowsett M et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer Clin Cancer Res 2001, 7:1230-1236. 11350888
20. Geisler J Helle H Ekse D Duong NK Evans DB Nordbo Y et al. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels Clin Cancer Res 2008, 14:6330-6335. 10.1158/ 1078-0432.CCR-07-5221 18829517
21. Miller WR Hawkins RA Forrest AP Significance of aromatase activity in human breast cancer Cancer Res 1982, 42:3365s-3368s. 7083201
22. Miller WR O'Neill JS The significance of steroid metabolism in human cancer J Steroid Biochem Mol Biol 1990, 37:317-325. 10.1016/ 0960-0760(90)90480-9 2257236
23. Santner SJ Feil PD Santen RJ In situ estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway J Clin Endocrinol Metab 1984, 59:29-33. 6725522
24. Sasano H Suzuki T Miki Y Moriya T Intracrinology of estrogens and androgens in breast carcinoma J Steroid Biochem Mol Biol 2008, 108:181-185. 10.1016/j.jsbmb.2007.09.012 17933521
25. Miller WR Anderson TJ Evans DB Krause A Hampton G Dixon JM An integrated view of aromatase and its inhibition J Steroid Biochem Mol Biol 2003, 86:413-421. 10.1016/S0960-0760(03)00352-2 14623539
26. Miller WR Larionov A Anderson TJ Walker JR Krause A Evans DB et al. Predicting response and resistance to endocrine therapy: Profiling patients on aromatase inhibitors Cancer 2008, 112:689-694. 10.1002/ cncr.23187 18072233
27. Brodie A Lu Q Yue W Wang J Liu Y Intratumoral aromatase model: The effects of letrozole (CGS 20267) Breast Cancer Res Treat 1998 49 Suppl 1 S23 S26 9797014 10.1023/A:1006028202087
28. Esteban JM Warsi Z Haniu M Hall P Shively JE Chen S Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation Am J Pathol 1992, 140:337-343. 1886419 1739127
29. Santen RJ Martel J Hoagland M Naftolin F Roa L Harada N et al. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts Breast Cancer Res Treat 1998, 49(Suppl 1):S93-S99. 9797023 10.1023/A:1006081729828
30. Sasano H Murakami H Immunolocalization of aromatase in human breast disorders using different antibodies Breast Cancer Res Treat 1998, 49(Suppl 1):S79-S84. 9797021 10.1023/A:1006009128920
31. Sasano H Edwards DP Anderson TJ Silverberg SG Evans DB Santen RJ et al. Validation of new aromatase monoclonal antibodies for immunohistochemistry: Progress report J Steroid Biochem Mol Biol 2003, 86:239-244. 10.1016/S0960-0760(03)00363-7 14623517
32. Sasano H Anderson TJ Silverberg SG Santen RJ Conway M Edwards DP et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry - a correlation with biochemical activities in 46 cases of breast cancer J Steroid Biochem Mol Biol 2005, 95:35-39. 10.1016/j.jsbmb.2005.04.027 16024247
33. Shenton KC Dowsett M Lu Q Brodie A Sasano H Sacks NP et al. Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas Breast Cancer Res Treat 1998, 49(Suppl 1):S101-S107. 9797024 10.1023/A:1006033813899
34. Brodie AM Lu Q Long BJ Fulton A Chen T Macpherson N et al. Aromatase and COX-2 expression in human breast cancers J Steroid Biochem Mol Biol 2001, 79:41-47. 10.1016/S0960-0760(01)00131-5 11850206
35. Brueggemeier RW Su B Sugimoto Y az-Cruz ES Davis DD Aromatase and COX in breast cancer: Enzyme inhibitors and beyond J Steroid Biochem Mol Biol 2007, 106:16-23. 10.1016/j.jsbmb.2007.05.021 17616393
36. Richards JA Petrel TA Brueggemeier RW Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells J Steroid Biochem Mol Biol 2002, 80:203-212. 10.1016/S0960-0760(01)00187-X 11897504
37. Simpson ER Mahendroo MS Means GD Kilgore MW Hinshelwood MM Graham-Lorence S et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis Endocr Rev 1994, 15:342-355. 8076586
38. Kamat A Hinshelwood MM Murry BA Mendelson CR Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans Trends Endocrinol Metab 2002, 13:122-128. 10.1016/S1043-2760(02)00567-2 11893526
39. Ristimaki A Sivula A Lundin J Lundin M Salminen T Haglund C et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Res 2002, 62:632-635. 11830510
40. Barnes N Haywood P Flint P Knox WF Bundred NJ Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence Br J Cancer 2006, 94:253-258. 10.1038/sj.bjc.6602932 16421596
41. Singh-Ranger G Salhab M Mokbel K The role of cyclooxygenase-2 in breast cancer: Review Breast Cancer Res Treat 2008, 109:189-198. 10.1007/ s10549-007-9641-5 17624587
42. Henriksen KL Rasmussen BB Lykkesfeldt AE Moller S Ejlertsen B Mouridsen HT Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: A comparison between whole sections and tissue microarrays J Clin Pathol 2007, 60:397-404. 10.1136/ jcp.2005.034447 16775123
43. Allred DC Harvey JM Berardo M Clark GM Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 1998, 11:155-168. 9504686
44. Henriksen KL Rasmussen BB Lykkesfeldt AE Moller S Ejlertsen B Mouridsen HT An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer Acta Oncol 2009, 48:522-531. 10.1080/02841860802676383 19173092
45. Harris L Fritsche H Mennel R Norton L Ravdin P Taube S et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364 17954709
46. Ellis MJ Miller WR Tao Y Evans DB Chaudri Ross HA Miki Y et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial Breast Cancer Res Treat 2009, 116(2):371-318. 18941892 2696016 10.1007/s10549-008-0161-8
47. Ellis MJ Tao Y Luo J A'Hern R Evans DB Bhatnagar AS et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 2008, 100:1380-1388. 2556704 18812550 10.1093/jnci/djn309
48. Salhab M Singh-Ranger G Mokbel R Jouhra F Jiang WG Mokbel K Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer J Surg Oncol 2007, 96:424-428. 10.1002/jso.20740 17657731
49. Gunnarsson C Jansson A Holmlund B Ferraud L Nordenskjold B Rutqvist LE et al. Expression of COX-2 and steroid converting enzymes in breast cancer Oncol Rep 2006, 16:219-224. 16820896
50. Oliveira VM Piato S Silva MA Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium Breast Cancer Res Treat 2006, 95:235-241. 10.1007/s10549-005-9010-1 16322898
51. Cirillo D Rachiglio AM la MR Giordano A Normanno N Leptin signaling in breast cancer: An overview J Cell Biochem 2008, 105:956-964. 10.1002/ jcb.21911 18821585
52. Hardy DB Janowski BA Chen CC Mendelson CR Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms Mol Endocrinol 2008 22 1812 1824 10.1210/me.2007-0443 18483177
53. Macdiarmid F Wang D Duncan LJ Purohit A Ghilchick MW Reed MJ Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha Mol Cell Endocrinol 1994, 106:17-21. 10.1016/0303-7207(94)90181-3 7895904
54. Reed MJ Coldham NG Patel SR Ghilchik MW James VH Interleukin-1 and interleukin-6 in breast cyst fluid: Their role in regulating aromatase activity in breast cancer cells J Endocrinol 1992, 132:R5-R8. 10.1677/ joe.0.132R005 1564416
55. Zhao Y Mendelson CR Simpson ER Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes Mol Endocrinol 1995, 9:340-349. 10.1210/me.9.3.340 7776980
56. Zhao Y Agarwal VR Mendelson CR Simpson ER Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene Endocrinology 1996, 137:5739-5742. 10.1210/en.137.12.5739 8940410
57. Purohit A Ghilchik MW Leese MP Potter BV Reed MJ Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues J Steroid Biochem Mol Biol 2005, 94:167-172. 10.1016/j.jsbmb.2005.01.015 15862962
58. Miki Y Suzuki T Tazawa C Yamaguchi Y Kitada K Honma S et al. Aromatase localization in human breast cancer tissues: Possible interactions between intratumoral stromal and parenchymal cells Cancer Res 2007, 67:3945-3954. 10.1158/0008-5472.CAN-06-3105 17440110